| Assessment of the pharmacogenomics educational needs of pharmacists KB McCullough, CM Formea, KD Berg, JA Burzynski, JL Cunningham, ... American journal of pharmaceutical education 75 (3), 51, 2011 | 198 | 2011 |
| Antineoplastic agents and the associated myelosuppressive effects: a review JN Barreto, KB McCullough, LL Ice, JA Smith Journal of pharmacy practice 27 (5), 440-446, 2014 | 134 | 2014 |
| Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies G Thanarajasingam, LM Minasian, F Baron, F Cavalli, RA De Claro, ... The Lancet Haematology 5 (11), e563-e598, 2018 | 113 | 2018 |
| Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients E Morsia, K McCullough, M Joshi, J Cook, HB Alkhateeb, A Al‐Kali, ... American journal of hematology 95 (12), 1511-1521, 2020 | 97 | 2020 |
| Development and evaluation of a pharmacogenomics educational program for pharmacists CM Formea, WT Nicholson, KB McCullough, KD Berg, ML Berg, ... American journal of pharmaceutical education 77 (1), 10, 2013 | 84 | 2013 |
| The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice SA Parikh, SJ Achenbach, TG Call, KG Rabe, W Ding, JF Leis, ... Cancer medicine 9 (10), 3390-3399, 2020 | 46 | 2020 |
| Safety and efficacy of infliximab therapy in the setting of steroid-refractory acute graft-versus-host disease FF Yalniz, M Hefazi, K McCullough, MR Litzow, WJ Hogan, R Wolf, ... Biology of Blood and Marrow Transplantation 23 (9), 1478-1484, 2017 | 43 | 2017 |
| Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice HD Finnes, KG Chaffee, TG Call, W Ding, SS Kenderian, DA Bowen, ... Leukemia & lymphoma 58 (6), 1376-1383, 2017 | 38 | 2017 |
| Evaluation of burnout in a national sample of hematology-oncology pharmacists AP Golbach, KB McCullough, SA Soefje, KC Mara, TD Shanafelt, ... JCO Oncology Practice 18 (8), e1278-e1288, 2022 | 32 | 2022 |
| Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation M Joshi, J Cook, K McCullough, A Nanaa, N Gangat, JM Foran, ... Blood cancer journal 11 (3), 49, 2021 | 30 | 2021 |
| A prospective survey of outpatient medication adherence in adult allogeneic hematopoietic stem cell transplantation patients LL Ice, GT Bartoo, KB McCullough, RC Wolf, RA Dierkhising, KC Mara, ... Biology of Blood and Marrow Transplantation 26 (9), 1627-1634, 2020 | 30 | 2020 |
| Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies KB McCullough, MA Hobbs, JP Abeykoon, P Kapoor Current hematologic malignancy reports 13, 114-124, 2018 | 27 | 2018 |
| Chronic myelomonocytic leukemia: a genetic and clinical update KB McCullough, MM Patnaik Current hematologic malignancy reports 10, 292-302, 2015 | 27 | 2015 |
| Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia N Gangat, I Johnson, K McCullough, F Farrukh, A Al-Kali, H Alkhateeb, ... Haematologica 107 (10), 2501, 2022 | 25 | 2022 |
| Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: data from a prospective series of patients AA Mangaonkar, KJ Langer, TL Lasho, C Finke, MR Litzow, WJ Hogan, ... John Wiley & Sons, Inc., 2023 | 24 | 2023 |
| Correlation of pain and fluoride concentration in allogeneic hematopoietic stem cell transplant recipients on voriconazole MR Barajas, KB McCullough, JA Merten, RA Dierkhising, GT Bartoo, ... Biology of Blood and Marrow Transplantation 22 (3), 579-583, 2016 | 21 | 2016 |
| Implementation of a pharmacogenomics education program for pharmacists CM Formea, WT Nicholson, CR Vitek, KK Wix, KB McCullough, ... American Journal of Health-System Pharmacy 75 (23), 1939-1946, 2018 | 20 | 2018 |
| Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: single institution experience R Nanah, K McCullough, W Hogan, K Begna, M Patnaik, M Elliott, ... American journal of hematology 92 (9), 866-871, 2017 | 18 | 2017 |
| Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts F Farrukh, D Chetram, A Al-Kali, J Foran, M Patnaik, T Badar, K Begna, ... American journal of hematology 97 (6), E210-E214, 2022 | 15 | 2022 |
| Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies G Thanarajasingam, LM Minasian, V Bhatnagar, F Cavalli, RA De Claro, ... The Lancet Haematology 9 (5), e374-e384, 2022 | 15 | 2022 |
